Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03396367 · ClinicalTrials.gov registry record · NA
Prevention and Risk: Treatment With a New Emphasis on Relationships
A NA study of HIV/AIDS and Drug Use, sponsored by Hunter College of City University of New York.
- Completed
- Registry status
- NA
- Development phase
- 196
- Enrollment target
- 1
- Study location
NCT03396367: Completed NA study of HIV/AIDS and Drug Use, sponsored by Hunter College of City University of New York.
NCT03396367 is a NA study of HIV/AIDS and Drug Use that has completed, run by Hunter College of City University of New York. The registered enrollment target is 196 participants, below the 33,177-participant average among 61 other HIV/AIDS trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03396367, a NA study of HIV/AIDS and Drug Use, has completed, sponsored by Hunter College of City University of New York.
- COMPLETED
- Registry status
- NA
- Development phase
- 196 participants
- Enrollment target
- 1
- Study location
Study Summary
This research examines the efficacy of an individually-delivered intervention tailored for YMSM in relationships. The intervention - termed PARTNER - utilizes a brief (4 session) motivational interviewing format to target Pre-Exposure Prophylaxis (PrEP) uptake/adherence, HIV transmission risk behavior, and associated drug use.
Primary Outcome
The self-reported number of illicit drug use days (not including marijuana) in the past 30 days
Conditions Studied
Interventions
- BEHAVIORAL PARTNER
- BEHAVIORAL Education Intervention
Study Locations (1)
New York
- Hunter College- City University of New York - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2018-02-14 |
| Est. Completion | 2024-02-21 |
| Phase | NA |
What the finished NCT03396367 record still lists
NCT03396367 is an interventional study that assigns participants to a tested intervention. The registered 196 participants enrollment target is mid-sized for trials with a published cap, below the 33,177-participant average among 61 other HIV/AIDS trials with a reported enrollment target (99% lower).
The record links to 5 conditions, with HIV/AIDS appearing as the primary indexed condition, and to 2 interventions - of which PARTNER is the first listed.
NCT03396367 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03396367 about?
NCT03396367 is a clinical study titled "Prevention and Risk: Treatment With a New Emphasis on Relationships". This research examines the efficacy of an individually-delivered intervention tailored for YMSM in relationships. The intervention - termed PARTNER - utilizes a brief (4 session) motivational interviewing format to target Pre-Exposure Prophylaxis (PrEP) uptake/adherence, HIV transmission risk behavi...
What is the current status of trial NCT03396367?
This trial is currently completed. It is a NA study. The enrollment target is 196 participants. The study started on 2018-02-14. Estimated completion is 2024-02-21.
What conditions does trial NCT03396367 study?
This clinical trial studies the following conditions: HIV/AIDS, Drug Use, Risk Reduction, Adherence, Medication, Sex, Anal.
What interventions are being tested in trial NCT03396367?
The interventions under investigation include: PARTNER (BEHAVIORAL), Education Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT03396367?
This trial is sponsored by Hunter College of City University of New York, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03396367 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV/AIDS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03396367's enrollment target sits among peer trials
196 28th of 61 higher than 33 of 61 other HIV/AIDS trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV/AIDS trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Mobile Gaming App to Improve Adherence to PrEP
RECRUITING · NA
-
LinkPositively+ A Mobile Health App Delivered Intervention to Improve HIV Care Outcomes Among Black Women Affected by Mental Health and Violence
RECRUITING · NA
-
MyPEEPS Mobile Plus: A Multi-Level HIV Prevention Intervention for Young MSM
RECRUITING · NA
-
MyPEEPS LITE Trial
RECRUITING · NA
-
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
RECRUITING · NA
-
Improving the Organizational Social Context to Address Structural Racism and Discrimination
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02822768 · 196 participants · NA
Packing Versus no Packing for Cutaneous Abscess
- NCT04250259 · 196 participants · Phase 2
SAMe Trial for Patients With Alcoholic Cirrhosis
- NCT05142592 · 196 participants · Phase 1
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
- NCT05317832 · 196 participants · Phase 2
Using Smartphones to Improve Physical Activity Levels of Individuals With Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI